These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 24550512)

  • 21. A personalised medicine approach for ponatinib-resistant chronic myeloid leukaemia.
    Korfi K; Mandal A; Furney SJ; Wiseman D; Somervaille TCP; Marais R
    Ann Oncol; 2015 Jun; 26(6):1180-1187. PubMed ID: 25712455
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The use of Imatinib resistance mutation analysis to direct therapy in Philadelphia chromosome/BCR-ABL1 positive chronic myeloid leukaemia patients failing Imatinib treatment, in Patan Hospital, Nepal.
    Kayastha GK; Ranjitkar N; Gurung R; Kc RK; Karki S; Shrestha R; Rajbhandari P; Thapa RK; Poudyal B; Acharya P; Roberts DJ; Hayes B; Zimmerman M; Basnyat B
    Br J Haematol; 2017 Jun; 177(6):1000-1007. PubMed ID: 28467002
    [TBL] [Abstract][Full Text] [Related]  

  • 23. As leukemia options grow, drugs jockey to be first-line therapies.
    Dolgin E
    Nat Med; 2013 Jan; 19(1):7. PubMed ID: 23295994
    [No Abstract]   [Full Text] [Related]  

  • 24. Overcoming clinical BCR-ABL1 compound mutant resistance with combined ponatinib and asciminib therapy.
    Eide CA; Brewer D; Xie T; Schultz AR; Savage SL; Muratcioglu S; Merz N; Press RD; O'Hare T; Jacob T; Vu TQ; Tognon CE; Macey TA; Kuriyan J; Kalodimos CG; Druker BJ
    Cancer Cell; 2024 Sep; 42(9):1486-1488. PubMed ID: 39214096
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
    Ferri C; Bianchini M; Bengió R; Larripa I
    Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sensitivity of imatinib-resistant T315I BCR-ABL CML to a synergistic combination of ponatinib and forskolin treatment.
    Oaxaca DM; Yang-Reid SA; Ross JA; Rodriguez G; Staniswalis JG; Kirken RA
    Tumour Biol; 2016 Sep; 37(9):12643-12654. PubMed ID: 27444277
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combining the ABL1 kinase inhibitor ponatinib and the histone deacetylase inhibitor vorinostat: a potential treatment for BCR-ABL-positive leukemia.
    Okabe S; Tauchi T; Kimura S; Maekawa T; Kitahara T; Tanaka Y; Ohyashiki K
    PLoS One; 2014; 9(2):e89080. PubMed ID: 24586514
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular analysis of the BCR-ABL1 kinase domain in chronic-phase chronic myelogenous leukemia treated with tyrosine kinase inhibitors in practice: study by the Nagasaki CML Study Group.
    Itonaga H; Tsushima H; Imanishi D; Hata T; Doi Y; Mori S; Sasaki D; Hasegawa H; Matsuo E; Nakashima J; Kato T; Horai M; Taguchi M; Matsuo M; Taniguchi H; Makiyama J; Sato S; Horio K; Ando K; Moriwaki Y; Sawayama Y; Ogawa D; Yamasaki R; Takasaki Y; Imaizumi Y; Taguchi J; Kawaguchi Y; Yoshida S; Joh T; Moriuchi Y; Nonaka H; Soda H; Fukushima T; Nagai K; Kamihira S; Tomonaga M; Yanagihara K; Miyazaki Y
    Leuk Res; 2014 Jan; 38(1):76-83. PubMed ID: 24262285
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance.
    Zhou T; Commodore L; Huang WS; Wang Y; Thomas M; Keats J; Xu Q; Rivera VM; Shakespeare WC; Clackson T; Dalgarno DC; Zhu X
    Chem Biol Drug Des; 2011 Jan; 77(1):1-11. PubMed ID: 21118377
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A role for FOXO1 in BCR-ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
    Wagle M; Eiring AM; Wongchenko M; Lu S; Guan Y; Wang Y; Lackner M; Amler L; Hampton G; Deininger MW; O'Hare T; Yan Y
    Leukemia; 2016 Jul; 30(7):1493-501. PubMed ID: 27044711
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.
    Wongboonma W; Thongnoppakhun W; Auewarakul CU
    Exp Mol Pathol; 2012 Apr; 92(2):259-65. PubMed ID: 22314255
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SNP array analysis of tyrosine kinase inhibitor-resistant chronic myeloid leukemia identifies heterogeneous secondary genomic alterations.
    Nowak D; Ogawa S; Müschen M; Kato M; Kawamata N; Meixel A; Nowak V; Kim HS; Kang S; Paquette R; Chang MS; Thoennissen NH; Mossner M; Hofmann WK; Kohlmann A; Weiss T; Haferlach T; Haferlach C; Koeffler HP
    Blood; 2010 Feb; 115(5):1049-53. PubMed ID: 19965645
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation.
    Pemovska T; Johnson E; Kontro M; Repasky GA; Chen J; Wells P; Cronin CN; McTigue M; Kallioniemi O; Porkka K; Murray BW; Wennerberg K
    Nature; 2015 Mar; 519(7541):102-5. PubMed ID: 25686603
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A thirty-five nucleotides BCR-ABL1 insertion mutation of controversial significance confers resistance to imatinib in a patient with chronic myeloid leukemia (CML).
    Marcé S; Cortés M; Zamora L; Cabezón M; Grau J; Millá F; Feliu E
    Exp Mol Pathol; 2015 Aug; 99(1):16-8. PubMed ID: 25913326
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictive models for designing potent tyrosine kinase inhibitors in chronic myeloid leukemia for understanding its molecular mechanism of resistance by molecular docking and dynamics simulations.
    Melge AR; Kumar LG; K P; Nair SV; K M; C GM
    J Biomol Struct Dyn; 2019 Nov; 37(18):4747-4766. PubMed ID: 30580670
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants.
    Soverini S; De Benedittis C; Castagnetti F; Gugliotta G; Mancini M; Bavaro L; Machova Polakova K; Linhartova J; Iurlo A; Russo D; Pane F; Saglio G; Rosti G; Cavo M; Baccarani M; Martinelli G
    BMC Cancer; 2016 Aug; 16():572. PubMed ID: 27485109
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemia.
    Kantarjian HM; Jabbour E; Deininger M; Abruzzese E; Apperley J; Cortes J; Chuah C; DeAngelo DJ; DiPersio J; Hochhaus A; Lipton J; Nicolini FE; Pinilla-Ibarz J; Rea D; Rosti G; Rousselot P; Shah NP; Talpaz M; Srivastava S; Ren X; Mauro M
    Am J Hematol; 2022 Nov; 97(11):1419-1426. PubMed ID: 36054756
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of ponatinib against ABL tyrosine kinase inhibitor-resistant leukemia cells.
    Okabe S; Tauchi T; Tanaka Y; Ohyashiki K
    Biochem Biophys Res Commun; 2013 Jun; 435(3):506-11. PubMed ID: 23684619
    [TBL] [Abstract][Full Text] [Related]  

  • 39. How does the novel T315L mutation of breakpoint cluster region-abelson (BCR-ABL) kinase confer resistance to ponatinib: a comparative molecular dynamics simulation study.
    Zhang H; He X; Ni D; Mou L; Chen X; Lu S
    J Biomol Struct Dyn; 2020 Jan; 38(1):89-100. PubMed ID: 30661457
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Imatinib resistance: obstacles and opportunities.
    Litzow MR
    Arch Pathol Lab Med; 2006 May; 130(5):669-79. PubMed ID: 16683885
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.